ChiCTR2000036478 版本V1.0 版本创建时间2020/08/23 22:31:01 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000036478 

最近更新日期:

Date of Last Refreshed on:

2020-08-23 22:29:59 

注册时间:

Date of Registration:

2020-08-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

网膜包裹胰肠吻合口对胰瘘及其他并发症影响前瞻性临床随机对照研究

Public title:

A prospective randomized controlled clinical study on the effect of omentum wrapped pancreaticojejunostomy on pancreatic fistula and other complications

注册题目简写:

English Acronym:

研究课题的正式科学名称:

网膜包裹胰肠吻合口对胰瘘及其他并发症影响前瞻性临床随机对照研究

Scientific title:

A prospective randomized controlled clinical study on the effect of omentum wrapped pancreaticojejunostomy on pancreatic fistula and other complications

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘健 

研究负责人:

刘健 

Applicant:

Jian Liu 

Study leader:

Jian Liu 

申请注册联系人电话:

Applicant telephone:

13918522382

研究负责人电话:

Study leader's telephone:

13918522382

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jianliu926@163.com

研究负责人电子邮件:

Study leader's E-mail:

Jianliu926@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市长海路225号胆道二科

研究负责人通讯地址:

上海市长海路225号胆道二科

Applicant address:

Department of biliary tract II,Changhai Road 225, Shanghai

Study leader's address:

Department of biliary tract II,Changhai Road 225, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

第二军医大学第三附属医院

Applicant's institution:

The Third Affiliated Hospital of the Second Military Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

EHBHKY2020-K-045

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

第二军医大学第三附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Third Affiliated Hospital of the Second Military Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-17 00:00:00

伦理委员会联系人:

王红阳

Contact Name of the ethic committee:

Hongyang Wang

伦理委员会联系地址:

上海市杨浦区长海路225号

Contact Address of the ethic committee:

Changhai No 225, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

第二军医大学第三附属医院

Primary sponsor:

The Third Affiliated Hospital of the Second Military Medical University

研究实施负责(组长)单位地址:

上海市长海路225号

Primary sponsor's address:

Changhai No 225, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

第二军医大学第三附属医院

具体地址:

上海市长海路225号

Institution
hospital:

The Third Affiliated Hospital of the Second Military Medical University

Address:

225 Changhai Road, Yangpu District

经费或物资来源:

自筹经费或申康临床三年行动计划

Source(s) of funding:

Self financing or Shenkang clinical three year action plan

Target disease:

Periampullary and pancreatic tumor

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机交叉对照 

Study design:

Cross-over 

研究目的:

研究术中胰肠吻合口网膜包裹对胰十二指肠切除术后并发症的影响  

Objectives of Study:

Objective to study the effect of omental wrapping of pancreaticojejunostomy on postoperative complications of pancreaticoduodenectomy

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄70岁以下,男女不限。
(2)ECOG评分≤2分。
(3)术前诊断壶腹周围肿瘤。
(4)术前影像学检查显示有条件完成肿瘤根治性切除,肠系膜上血管无肿瘤实质性侵润者。
(5)术中探查未发现肠系膜根部等远处淋巴结转移。
(6)行胰十二指肠切除及8、9、12、13组淋巴结及后腹膜淋巴结清扫。
(7)愿意并签署知情同意书。

Inclusion criteria

(1) They are under 70 years old, male and female.

(2) ECoG score ≤ 2.

(3) Preoperative diagnosis of periampullary tumor.

(4) Preoperative imaging examination showed that radical resection of the tumor could be completed, and there was no invasion of the superior mesenteric vessels.

(5) No distant lymph node metastasis such as mesenteric root was found during the operation.

(6) Pancreatoduodenectomy and lymph node dissection were performed in 8,9,12,13 groups.

(7) Willing to sign the informed consent form.

排除标准:

(1)术中探查发现肿瘤有肝内转移、远处脏器转移或腹腔内种植转移,无肿瘤根治条件。
(2)淋巴结转移已超出可根治性切除范围。
(3)无条件实施肿瘤根治性切除。
(4)术中发现大量腹水、患者全身情况不稳定、不能进一步耐受重大手术。
(5)有其他任何严重疾病,研究者认为可能影响患者的治疗、随访或评估。包括任何未被控制的有临床意义的心脏、肺、肾脏、消化、神经、精神疾病、免疫调节性疾病、代谢性疾病及传染病等。
(6)不能或不愿提供知情同意书或不能遵守试验要求者。

Exclusion criteria:

(1) Intraoperative exploration revealed intrahepatic metastasis, distant organ metastasis or intraperitoneal implantation metastasis.

(2) Lymph node metastasis is beyond the scope of radical resection.

(3) Radical resection was performed unconditionally.

(4) A large amount of ascites was found during the operation, the patient's general condition was unstable, and he could not tolerate the major operation.

(5) There are any other serious diseases that the researchers believe may affect the treatment, follow-up or evaluation of the patients. It includes any uncontrolled and clinically significant heart, lung, kidney, digestive, neurological, mental illness, immune regulatory disease, metabolic disease and infectious disease.

(6) Those who are unable or unwilling to provide informed consent or fail to comply with the test requirements.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 1990-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 1990-01-01 00:00:00  

干预措施:

Interventions:

组别:

常规组

样本量:

40

Group:

Conventional group

Sample size:

干预措施:

网膜包裹组

干预措施代码:

Intervention:

mental wrapping group

Intervention code:

组别:

试验组

样本量:

40

Group:

Experimental group

Sample size:

干预措施:

术中胰肠吻合口网膜包裹

干预措施代码:

Intervention:

omental wrapping of pancreaticojejunostomy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

第二军医大学第三附属医院 

单位级别:

三甲医院 

Institution
hospital:

The Third Affiliated Hospital of the Second Military Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

淀粉酶

指标类型:

主要指标

Outcome:

amylase

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

引流液

组织:

Sample Name:

Drainage fluid

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计学专家设计好后,以信封封存,手术结束前,由对病情不知晓第三者拆信封,确定是否行网膜包裹

Randomization Procedure (please state who generates the random number sequence and by what method):

Statistics experts designed, sealed in envelopes, before the end of the operation, by the third party who did not know the condition of the disease to open the envelope to determine whether the omentum package

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束,网络平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

End of study, network platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一为病例记录表,二为电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-23 22:29:59